Shots:
- Formycon has entered into an exclusive licensing & supply agreement with MS Pharma for the commercialization of Formycon’s FYB206, a biosimilar version of Merck’s Keytruda (pembrolizumab), in the MENA region
- As per the deal, Formycon will receive an upfront payment, potential development & regulatory milestones, & a significant share of regional gross profits, though financial terms were not disclosed. The deal also incl. an option for future tech transfer
- FYB206 is a humanized monoclonal antibody against PD-1 receptors that is approaching the end of its clinical development phase, with 1EP results expected in the Q1’26
Ref: PRnewswire | Image: Formycon & MS Pharma | Press Release
Related News: Actor Pharmaceuticals and Megalabs Collaborate with Formycon to commercialize FYB203 (Biosimilar, Eylea) in Australia and LATAM
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
